Ulf Björklund
Chairman presso REDWOOD PHARMA AB
Profilo
Ulf Björklund currently works at Ub-Consulting AB, as Chief Executive Officer & Director, Redwood Pharma AB, as Chairman & Chief Medical Officer from 2023, Lipum AB, as Chairman from 2016, Stayble Therapeutics AB, as Chairman from 2021, and Nimutan AB, as Director from 2019.
Mr. Björklund also formerly worked at Aprea Therapeutics AB, as Chief Executive Officer from 2010 to 2016, OxyPharma AB, as Chief Executive Officer from 2002 to 2010, Wntresearch AB, as Chairman from 2018 to 2019, ProNoxis AB, as Director, TikoMed AB, as Director, Aptahem AB, as Director-Clinical Research, Annexin Pharmaceuticals AB, as Director, and Synartro AB, as Chief Scientific Officer.
Mr. Björklund received his graduate degree from the University of Uppsala.
Posizioni attive di Ulf Björklund
| Società | Posizione | Inizio |
|---|---|---|
| REDWOOD PHARMA AB | Chairman | 01/01/2023 |
| LIPUM AB | Chairman | 01/01/2016 |
| NIMUTAN AB (PUBL) | Director/Board Member | 01/05/2019 |
| STAYBLE THERAPEUTICS AB | Chairman | 02/06/2021 |
| Ub-Consulting AB | Chief Executive Officer | - |
Precedenti posizioni note di Ulf Björklund
| Società | Posizione | Fine |
|---|---|---|
Aptahem AB
 Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | Chief Operating Officer | 14/01/2022 |
| WNTRESEARCH AB | Chairman | 01/06/2019 |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Chief Executive Officer | 01/04/2016 |
| OxyPharma AB | Chief Executive Officer | 01/10/2010 |
| ░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - |
Formazione di Ulf Björklund
| University of Uppsala | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 6 |
|---|---|
| WNTRESEARCH AB | Health Technology |
 | Health Technology |
| REDWOOD PHARMA AB | Health Technology |
| LIPUM AB | Health Technology |
| STAYBLE THERAPEUTICS AB | Health Technology |
| ANNEXIN PHARMACEUTICALS AB | Health Technology |
| Aziende private | 7 |
|---|---|
Nimutan AB
 Nimutan AB Household/Personal CareConsumer Non-Durables Nimutan AB engages in the development, marketing, and sale of nutritional products and food supplements. It operates through the following segments: Brand Sales; Production, Innovation, and Private Label; and Corporate. It sells a variety of products for men and women's health, joint health, and skin care. The company was founded by Bengt Johansson on November 15, 2005 and is headquartered in Jönköping, Sweden. | Consumer Non-Durables |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
ProNoxis AB
 ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Health Technology |
| OxyPharma AB | |
TikoMed AB
 TikoMed AB Pharmaceuticals: MajorHealth Technology TikoMed AB is a Swedish pharmaceutical company that develops pharmaceutical products. The private company is based in Viken, Sweden. The company was founded by Adam Bruce, Lars Bruce. Anders Kristensson has been the CEO of the company since 2018. | Health Technology |
| Ub-Consulting AB | |
| Synartro AB |
- Borsa valori
- Insiders
- Ulf Björklund
